1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/63455
Full metadata record
DC FieldValueLanguage
dc.creatorPedro Pires Goulart Guimarãespt_BR
dc.creatorCelso Tarso Rodrigues Vianapt_BR
dc.creatorLuciana Xavier Pereirapt_BR
dc.creatorSávio Morato Lacerda Gontijopt_BR
dc.creatorPaula Peixoto Campospt_BR
dc.creatorSilvia Passos Andradept_BR
dc.creatorRobson Augusto Souza dos Santospt_BR
dc.creatorRubén Dario Sinisterra Millánpt_BR
dc.date.accessioned2024-01-29T13:42:20Z-
dc.date.available2024-01-29T13:42:20Z-
dc.date.issued2022-
dc.citation.volume19pt_BR
dc.citation.issue6pt_BR
dc.citation.spage676pt_BR
dc.citation.epage685pt_BR
dc.identifier.doihttps://doi.org/10.2174/1567201818666210729110127pt_BR
dc.identifier.issn1875-5704pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/63455-
dc.description.resumoBackground: Colorectal cancer (CRC) is the third most common cancer in the world. 5- Fluorouracil (5-FU) is a conventional and most effective drug used in the clinic for the treatment of CRC. However, the clinical use of 5-FU is limited due to the acquired resistance and systemic toxicity, such as hepatotoxicity and gastrointestinal toxicity. Objective: Recent advances in nanomedicine are being exploited to develop nanoparticle platforms to overcome resistance and therapeutic delivery of active molecules. Here, we developed 5-FU loaded sulfadiazine-poly(lactide-co-glycolide) nanoparticles (SUL-PLGA NPs) to be applied in the colorectal cancer model. Methods: We assessed the in vivo efficacy of the SUL-PLGA NPs to enhance the antitumor effect of 5-FU. Results: In vivo treatment with 5-FU-SUL-PLGA NPs significantly reduced tumor growth in a colon cancer xenograft model compared to free 5-FU and 5-FU loaded non-targeted NPs. Treatment with 5-FU-SUL-PLGA NPs also increased blood vessel diameters within tumors, which could act in conjunction to enhance antitumor efficacy. In addition, 5-FU-SUL-PLGA NPs significantly reduced liver mass and lung mass, which are the most common metastasis sites of CRC, and decreased liver hepatotoxicity compared to free 5-FU drug and 5-FU loaded non-targeted NPs. Conclusion: Our findings suggest that the use of 5-FU-SUL-PLGA NPs is a promising strategy to enhance 5-FU efficacy against CRC.pt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORApt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE FISIOLOGIA E BIOFÍSICApt_BR
dc.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIApt_BR
dc.publisher.departmentICX - DEPARTAMENTO DE QUÍMICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofCurrent Drug Deliverypt_BR
dc.rightsAcesso Restritopt_BR
dc.subjectPLGApt_BR
dc.subjectPolymeric nanoparticlespt_BR
dc.subjectSulfonamidept_BR
dc.subjectDrug deliverypt_BR
dc.subjectColorectal cancerpt_BR
dc.subjectCancer therapypt_BR
dc.subject.otherNanopartículaspt_BR
dc.subject.otherCâncer - Tratamentopt_BR
dc.subject.otherCólon (Anatomia) - Câncerpt_BR
dc.subject.otherSistema de distribuição de medicamentospt_BR
dc.subject.otherSistemas deliberados de drogas poliméricaspt_BR
dc.subject.otherÁcidos sulfônicospt_BR
dc.titleSulfonamide-functionalized polymeric nanoparticles for enhanced in vivo colorectal cancer therapypt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://www.eurekaselect.com/article/116952pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-4534-2779pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-9407-3870pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-7803-4345pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0003-2016-2210pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-7656-1849pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.